Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The American Journal of Hospice & Palliative Care|March 5, 2016
Perspectives of Health-Care Providers Toward Advance Care Planning in Patients With Advanced Cancer and Congestive Heart FailureManisha Chandar, Bruce Brockstein, Alan Zunamon, et al.
Diabetes Care|February 13, 2010
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemiaRonald B Goldberg, John R Guyton, Theodore Mazzone, et al.
Journal of Clinical Lipidology|February 5, 2011
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetesRuth S Weinstock, Ronald B Goldberg, John R Guyton, et al.
Journal of Lipid Research|April 13, 2012
The role of oxysterols in control of endothelial stiffnessTzu Pin Shentu, Dev K Singh, Myung-Jin Oh, et al.
JAMA|November 15, 2006
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trialTheodore Mazzone, Peter M Meyer, Steven B Feinstein, et al.
Biochemical and Biophysical Research Communications|August 10, 2010
Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic modelYong Zhao, Chengshan Guo, David Hwang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 19, 2014
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)Michael H Davidson, Robert S Rosenson, Kevin C Maki, et al.
BMC Medicine|January 12, 2012
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cellsYong Zhao, Zhaoshun Jiang, Tingbao Zhao, et al.
Stroke|August 1, 2013
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialDavid Preiss, Thomas D Giles, Laine E Thomas, et al.
BMJ Open|December 4, 2012
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialDavid Preiss, Laine E Thomas, Jie-Lena Sun, et al.
Pageof 8